Stallergenes Greer

Stallergenes Greer Ltd is a global biopharmaceutical company headquartered in London, specializing in the diagnosis and treatment of respiratory allergies through immunotherapy.
Stallergenes Greer Ltd is the parent company of GREER Laboratories, Inc. (registered office in the U.S.) and Stallergenes S.A.S. (registered office in France).
With 1139 employees in 2019, Stallergenes Greer operates in 19 countries.
Stallergenes Greer's core manufacturing facilities are located both in Europe (Antony and Amilly in France) and in the USA (Lenoir, North Carolina and San Diego, California).
History.
Stallergenes was founded in 1962 by Institut Mérieux In 2015, Stallergenes and Greer Laboratories Inc. merged to form Stallergenes Greer, "a worldwide leader in allergy immunotherapy".
Greer was founded by R.T. Greer, a collecter of source materials (i.e. : roots, herbs, pollens) in 1904.
Stallergenes Greer is a privately held company owned by Waypoint Capital, chaired by Ernesto Bertarelli.
Activity.
Stallergenes Greer is specialised in allergy immunotherapy treatments. It includes Name Patient Products (NPP) which are allergen products, prepared in accordance with prescriptions for individual patients.
The product portfolio covers different segments including: sublingual products (Staloral®, Oralair®, Actair®), subcutaneous products (Alustal®/Phostal®, Alyostal®/Albey®), allergen extracts available as bulk extract or NPP, veterinary products, testing supplies, source materials and other supplies like sterile diluents, sterile empty vials.
Board of directors.
The board of directors includes:
A pharmaceutical and clinical development programme.
Since 2003, Stallergenes has been involved in a clinical development programme whose objective is to develop proprietary medicines intended to cover the main allergens responsible for more than 80% of respiratory allergies. 
Oralair is the first sublingual immunotherapy tablet resulting from this programme. Oralair is marketed in 22 countries and has been approved by the Food and Drug Administration in the United States.
The second project in this programme is the house dust mite immunotherapy tablet Actair which is marketed in Japan, Australia, and New Zealand.